Global Blood Therapeutics - GBT Stock Forecast, Price & News

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last twelve months. There are currently 11 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GBT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GBT, but not buy additional shares or sell existing shares.
View GBT analyst ratings or view top-rated stocks.

14 Wall Street research analysts have issued 12-month price targets for Global Blood Therapeutics' shares. Their GBT share price forecasts range from $31.00 to $75.00. On average, they expect the company's share price to reach $65.42 in the next twelve months. This suggests that the stock has a possible downside of 4.5%.
View analysts price targets for GBT or view top-rated stocks among Wall Street analysts.

Global Blood Therapeutics' stock was trading at $29.27 at the beginning of the year. Since then, GBT stock has increased by 134.0% and is now trading at $68.49.
View the best growth stocks for 2022 here.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) issued its earnings results on Thursday, November, 4th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($1.10) by $0.03. The company had revenue of $52.05 million for the quarter, compared to the consensus estimate of $53.69 million. Global Blood Therapeutics had a negative net margin of 137.30% and a negative trailing twelve-month return on equity of 170.37%. The business's revenue was up 41.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.97) EPS.

20 employees have rated Global Blood Therapeutics Chief Executive Officer Ted W. Love, M.D. on Glassdoor.com. Ted W. Love, M.D. has an approval rating of 100% among the company's employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Global Blood Therapeutics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Block (SQ).

(GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Global Blood Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.31%), BlackRock Inc. (7.04%), Pentwater Capital Management LP (4.74%), State Street Corp (3.53%), Perceptive Advisors LLC (3.44%) and UBS Oconnor LLC (3.32%). Insiders that own company stock include Dawn Svoronos, Eric Fink, Jeffrey S Farrow, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Nazila Habibizad, Philip A Pizzo, Scott W Morrison, Ted W Love, Tricia Borga Suvari and Willie L Jr Brown.
View institutional ownership trends.

Shares of GBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GBT stock can currently be purchased for approximately $68.49.

Global Blood Therapeutics (NASDAQ:GBT) has a market capitalization of $4.62 billion and generates $194.75 million in revenue each year. The company earns $-303,090,000.00 in net income (profit) each year or ($5.01) on an earnings per share basis.

The company employs 457 workers across the globe.

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.gbt.com. The company can be reached via phone at (650) 741-7700 or via email at investor@gbt.com.